Ludwig Cancer Research engages leading scientists and clinicians in an integrated effort to understand and confront the challenge of cancer. The Oxford Branch is based at the University of Oxford, UK and benefits from excellent links with the global Ludwig Cancer Research and local Oxford research communities.
Ludwig Oxford Branch researchers are investigating all stages of cancer, from the risk of disease through to new treatment opportunities. Our research groups are interested in the signalling pathways that influence cancer initiation and progression, with a focus on infection, inflammation and cancer epigenetics. We aim to advance cancer prevention, early diagnosis and effective treatment. Find out more about the Ludwig Oxford research groups.
Latest News
Vacancy: Postdoctoral Research Scientist - Epigenetic Mechanisms
3 December 2019
Fatty acid metabolism in melanoma
14 November 2019
Ludwig Oxford at NCRI Cancer Conference 2019
4 November 2019
FOLLOW US
Recent publications
-
Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion
Journal article
Vergari E. et al, (2019), Nature Communications, 10
-
ZNF281/Zfp281 is a target of miR-1 and counteracts muscle differentiation.
Journal article
Nicolai S. et al, (2019), Molecular oncology
-
p63 Is a Promising Marker in the Diagnosis of Unusual Skin Cancer
Journal article
Smirnov A. et al, (2019), International Journal of Molecular Sciences, 20, 5781 - 5781
-
Predicting the difficult laparoscopic cholecystectomy: development and validation of a pre-operative risk score using an objective operative difficulty grading system.
Journal article
Nassar AHM. et al, (2019), Surgical endoscopy
Seminars
Outreach
Study with us
Work with us
